



DIGITAL HEALTH
ACCELERATOR

dxdhub
DIAGNOSTICS DEVELOPMENT HUB

An Introduction to Diagnostics Development Hub (DxD Hub)

Diagnostics for Our Future

www.dxdhub.sg
enquiry@dxdhub.sg

**10 Biopolis Road, Chromos, #03-01,
Singapore 138670**

 Agency for
Science, Technology
and Research
SINGAPORE

ARES_CONFIDENTIAL

ABOUT DXD HUB

2014

Launched



A Singapore National Platform with Dual Mission


Bridges the diagnostics **productization gap** in Singapore and brings translational research IPs to markets as validated registered diagnostics products

Catalyzes the **diagnostics medtech ecosystem** in Singapore by attracting research and private investment to Singapore


Our Multi-disciplinary Team

Internal Multi-Disciplinary Skills Supporting Concept to Registration

Partnerships & Project Management	IVD Development	SaMD Development	IMT Development	Regulatory	Quality Management Systems	Adoption
Partnerships	Molecular Dx	Software Engineering	BioMedical Engineering	Regulatory Roadmap & Strategy	ISO 13485 (Medical Device)	Clinical Dx Lab
Product Dev & Project Management	Protein Dx	Interoperability Engineering	Design - ID, UI/UX		ISO 14971 (Risk Management)	Clinical Deployment
	Pathology	Data Science - Bioinformatics	Firmware Engineering		IEC62304 (Medical Software)	Commercial Lab Ops
	Pilot Manufacturing	UI/UX Designing	Mechanical Engineering			Digital Health Accelerator
		Systems Engineering	Design Engineering			



Focus on Diagnostics Productization



Priority Areas:

- Precision Medicine
- Women's Health
- Infectious Diseases

Supported by DxD Hub capabilities in

- In Vitro Diagnostics (IVD)
- Digital Diagnostics (DDx)
- De-centralised Care



Nobody is safe, until everyone is safe

Nobody Is Safe, Until Everyone Is Safe

ASEAN Dx Initiative is a platform endorsed by the ASEAN Committee of Science, Technology and Innovation.

- Co-chaired by Diagnostics Development Hub (DxD Hub) & Philippine Council for Health Research and Development (PCHRD)
- Mandate to build diagnostic capacity among ASEAN member countries.

TIMELY COMMITMENT BY ASEAN LEADERS in 2019

Capability
Development:
Delivering Dx
Innovations by
ASEAN for
ASEAN

Capacity
Building: Sharing
of Best Practices
Strengthening
Bonds



Singapore To Catalyse ASEAN Medical Diagnostics Initiative
And Deepen Regional Connectivity



The ASEAN Dx Initiative was conceptualized by COST-75 in 2018, and officially launched at by 18th ASEAN Ministerial Meeting in Oct 2019 for capability development and capacity building amongst ASEAN member states.

DxD Hub – A Diagnostic Pillar to Build Capabilities and Capacity for Pandemic Preparedness



DxD Hub leads the Diagnostics Cooperative

1. To accelerate the delivery of regulatory approved diagnostics with production capacity
2. To ensure supply chain readiness
3. To expedite speedy deployment of national testing

COVID-19 Diagnostics Solutions – Quick response to the unprecedented crisis

Fortitude Series



- First “ready-made” COVID-19 hospital lab diagnostic test kit approved for clinical use in Singapore, launched within a month of the virus sequence’s publication online
- The test range has since expanded to meet greater global needs in infectious disease testing
- 9M+ Fortitude test kits deployed to > 45 countries


Fortitude 3.0

- Obtained Provisional Authorisation from HSA and has CE-mark

Fortitude Syndromic

- Beyond testing for COVID-19, this kit has additional PCR primers designed to detect Influenza A and B

RESOLUTE Series



- World’s first multiplex direct-PCR for SARS-CoV-2 detection test
 - Utilised in Changi Airport's testing facility to support the reopening of the border
 - Received the Defence Technology Prize (DTP) by MINDEF in 2021
- The latest iterations available are RESOLUTE 2.0 and RESOLUTE 3.0
 - Obtained HSA Provisional Authorisation and CE-mark
 - 3.5M+ RESOLUTE tests deployed



Diagnostics Products & Services Co-Developed with Public and Private Partners

GASTROClear




- First-in-the world miRNA-based liquid biopsy that can detect 87.5% of stage I gastric cancers and 89.5% of stage II gastric cancers
- Attained CE mark in 2017 and HSA clearance in 2019
- Set standard for microRNA-based diagnostics tests – used as an exemplar in the drafting of Singapore Standard 656
- Test deployed in >10 cities in China, Vietnam, Singapore

UNITED™ (Tissue500™)

- Pan-cancer assay to enable Asian-centric molecular characterisation of tumors based on next-generation sequencing technology
- Commercial launch in Sep 2021. Test is offered as a LDT by Lucence and service is provided by Lucence’s CAP lab in SG, serving local and regional hospitals
- Showcased in Frontiers in Cancer Science Conference 2021 and USCAP 2022 annual meeting



FxMammo



- In collaboration with NUS and NUHS
- An AI-powered diagnostics solution, which improves predictive accuracy of digital mammography – reduced false positive rates from 9% to 2% and reduced recall rates by 67%
- Attained SaMD HSA clearance in 2022

aiTriage™



- In collaboration with TIIM and SGH to refine and clinically validate the aiTriage™ system, an AI-powered diagnostic solution for rapid, real-time risk prediction for Major Adverse Cardiac Event (MACE)
- Shortens triage time significantly and enables better allocation of healthcare manpower for patient care
- HSA Class C Medical Device Registration



Digital Health Accelerator



In Digital Health... A Chasm Exists Between Demand & Supply...

dxdhub

**Care
Providers**

Productisation

**Adoption &
Initial Scaling**

Innovators

I have a
problem...


UI/UX
Interoperability
Regulatory Clearance
Quality Systems
Clinical Data Access
Verification & Validation

Implementation
Integration
Cybersecurity
Workflow
Re-Engineering

I have a
solution...

DHA Addresses Productisation and Commercialisation Challenges with Two Project Types

Project Scope and Approach Will be Customised based by DHA Project Managers based on Collaborator Needs



DHA Projects Involve Contributions From All Parties

	Example Activities	Innovator	DHA	Health System
Productisation	QMS (ISO13485) Implementation	●	●	
	UI/UX, Workflow Design		●	
	AI Model Fine Tuning/Training		●	
	SW Dev, Documentation & Testing	●	●	
	Interoperability Engineering		●	●
	Clinical Validation	●	●	●
	Regulatory Submission Dossier	●	●	
Adoption & Initial Scaling	Baseline Performance		●	●
	Solution Validation	●	●	●
	Pilot Implementation	●	●	●
	Solutions Architecture (w/ Synapse)		●	
	Integration Engineering	●	●	
	Process Re-Engineering		●	●
	Clinical Implementation	●	●	●
	Benefits Quantification	●	●	●

GUIDANCES ON DIGITAL HEALTH PRODUCTS & SERVICES

From HSA




Digital Health Products that are Medical Devices (www.hsa.gov.sg/medical-devices/digital-health)

 <p>Screening / Diagnosis</p> <p>Software used by healthcare providers to screen and grade Diabetic Retinopathy through fundus images.</p> <p>The screening can be conducted at a satellite clinic, while the results are verified by the eye specialist in another location.</p>	 <p>Tele-Monitoring</p> <p>Wearable devices used to perform remote monitoring of patient's physiological parameters for chronic disease management.</p>	 <p>Tele-Treatment</p> <p>Remote Surgical Systems that allow doctors to perform remote surgery on a patient who is not physically in the same location.</p>	 <p>Digital Therapeutics</p> <p>Software/mobile application used to treat or manage conditions such as substance use disorder, insomnia, diabetes etc.</p>
---	---	---	--





From MOH – AI in Healthcare Guidelines (moh.gov.sg)

ARTIFICIAL INTELLIGENCE IN HEALTHCARE GUIDELINES (AIHGle)

Developed by:

Endorsed by:

Published Oct 2021



Celebrating 10 years of
Collaborative Excellence in Diagnostics

Diagnostics For Our Future

dxdhub
DIAGNOSTICS DEVELOPMENT HUB

THANK YOU

For more information, visit

<https://www.a-star.edu.sg/dxdhub>